Androgen dynamics and serum PSA in patients treated with abiraterone acetate

Prostate Cancer and Prostatic Diseases

Volumn 17, Issue 2, 2014, Pages 192-198

  Ryan, C J ^a   Peng, W ^b   Kheoh, T ^b   Welkowsky, E ^b   Haqq, C M ^b   Chandler, D W ^c   Scher, H I ^d   Molina, A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c LABORATORY CORPORATION OF AMERICA   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANDROSTENEDIONE; PLACEBO; PRASTERONE SULFATE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; 17-(3-PYRIDYL)-5,16-ANDROSTADIEN-3BETA-ACETATE; ABIRATERONE; ANDROGEN; ANDROSTANE DERIVATIVE; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MOLECULAR DYNAMICS; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TANDEM MASS SPECTROMETRY; TESTOSTERONE BLOOD LEVEL; BLOOD; CLINICAL TRIAL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME;

ANDROGENS; ANDROSTENES; DOUBLE-BLIND METHOD; HUMANS; KALLIKREINS; MALE; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84901188408     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2014.8     Document Type: Article

References (26)

1. Bonkhoff H, Berges R. From pathogenesis to prevention of castration resistant prostate cancer. Prostate 2010; 70: 100-112
2. Van Allen EM, Ryan CJ. Novel secondary hormonal therapy in advanced prostate cancer: An update. Curr Opin Urol 2009; 19: 315-321
3. Hofland J, Van Weerden WM, Dits NF, Steenbergen J, Van Leenders GJ, Jenster G et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res 2010; 70: 1256-1264
4. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-3748
5. Danila DC, Morris MJ, De Bono JS, Ryan CJ, Denmeade SR, Smith MR et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-Treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496-1501
6. O'Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M et al. Hormonal impact of the 17alpha-hydroxylase/C(17, 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004; 90: 2317-2325
7. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28: 1489-1495
8. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011; 17: 4854-4861
9. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebocontrolled phase 3 study. Lancet Oncol 2012; 13: 983-992
10. Ryan CJ, Smith MR, De Bono JS, Molina A, Logothetis CJ, De Souza P et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-148
11. Ryan CJ, Molina A, Li J, Kheoh T, Small EJ, Haqq CM et al. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: Results from an analysis of a randomized phase III trial. J Clin Oncol 2013; 31: 2791-2798
12. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
13. Scher HI, Kelly WM, Zhang ZF, Ouyang P, Sun M, Schwartz M et al. Post-Therapy serum prostate-specific antigen level and survival in patients with androgenindependent prostate cancer. J Natl Cancer Inst 1999; 91: 244-251
14. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: The new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011; 29: 3651-3658
15. Stanford JL, Noonan EA, Iwasaki L, Kolb S, Chadwick RB, Feng Z et al. A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 243-247
16. Hamada A, Danesi R, Price DK, Sissung T, Chau C, Venzon D et al. Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgenindependent prostate cancer. Urology 2007; 70: 217-220
17. Wright JL, Kwon EM, Lin DW, Kolb S, Koopmeiners JS, Feng Z et al. CYP17 polymorphisms and prostate cancer outcomes. Prostate 2010; 70: 1094-1101
18. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration- resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563-4571
19. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28: 1481-1488
20. Russell GM, Henley DE, Leendertz J, Douthwaite JA, Wood SA, Stevens A et al. Rapid glucocorticoid receptor-mediated inhibition of hypothalamic- pituitaryadrenal ultradian activity in healthy males. J Neurosci 2010; 30: 6106-6115
21. Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 2012; 30: 637-643
22. Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: Results from a cancer and leukemia group B study. Clin Cancer Res 2007; 13: 2030-2037
23. Scher HI, Halabi S, Tannock I, Higano C, Bubley GJ, Dreicer R et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159
24. Leppert JT, Lam JS, Butch AW, Belldegrun AS. The sensitivity of testosterone immunoassays and their role in monitoring antiandrogen therapy. Urol Oncol 2006; 24: 277-278
25. Matsumoto AM, Bremner WJ. Serum testosterone assays-Accuracy matters. J Clin Endocrinol Metab 2004; 89: 520-524
26. Vesper HW, Bhasin S, Wang C, Tai SS, Dodge LA, Singh RJ et al. Interlaboratory comparison study of serum total testosterone [corrected] measurements performed by mass spectrometry methods. Steroids 2009; 74: 498-503